Delving into the Latest Updates on Liraglutide (Hybio) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms-

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Hybio Pharmaceutical Co.. Ltd.

Active Organization

Hybio Pharmaceutical Co.. Ltd.

Inactive Organization-

License Organization

Hybio Pharmaceutical Co.. Ltd.Hikma Pharmaceuticals USA, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (23 Dec 2024),

Diabetes Mellitus, Type 2

Regulation-

Login to view timeline

深圳翰宇药业股份有限公司生产的利拉鲁肽注射液为受试制剂，诺和诺德公司生产的利拉鲁肽注射液（商品名：诺和力）为参比制剂，在二甲双胍治疗3个月以上血糖控制不佳的2型糖尿病患者中进行随机、平行、对照、开放、多次给药PK/PD对比研究，评估药代动力学和药效动力学指标相似性，及安全性。

[Translation]

Liraglutide injection produced by Shenzhen Hanyu Pharmaceutical Co., Ltd. was the test preparation, and liraglutide injection (trade name: Victoza) produced by Novo Nordisk was the reference preparation. A randomized, parallel, controlled, open, multiple-dose PK/PD comparison study was conducted in patients with type 2 diabetes who had poor blood sugar control after metformin treatment for more than 3 months to evaluate the similarity of pharmacokinetic and pharmacodynamic indicators, as well as safety.

Start Date03 Jul 2019

Sponsor / Collaborator

Hybio Pharmaceutical Co.. Ltd.

100 Clinical Results associated with Liraglutide (Hybio)

Login to view more data

100 Translational Medicine associated with Liraglutide (Hybio)

Login to view more data

100 Patents (Medical) associated with Liraglutide (Hybio)

Login to view more data

100 Deals associated with Liraglutide (Hybio)

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Hybio Pharmaceutical Co.. Ltd.	23 Dec 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EASD2018	Not Applicable	-	-	Dulaglutide	jbfuclpmmr(jbxhrabinp): OR = 1.76 (95% CI, 1.56 - 1.99) View more	Positive	02 Oct 2018
				Liraglutide

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data